Diabetic Neuropathic Pain Pathophysiology and Pain Management.

Diana Christine Laleno1, Chilafat Dalimunte2

1Department of Anesthesiology & Intensive Therapy, Medical Faculty of Sam Ratulangi University, Prof. RD Kandoa Hospital, Permata Bunda General Hospital, Manado-Indonesia.
2Department of Anesthesiology, SOS Freeport Hospital, Mitra Kemayoran Hospital, Jakarta-Indonesia.

Abstract

Background: Diabetes Mellitus (DM) is the most common cause of neuropathy in the Western world. There are 12,000,000 patients with non-insulin dependent DM (NIDDM) in the USA and 1,000,000 patients with insulin dependent DM (IDDM). At present 20% of people more than 65 years old have DM, by 2010 it will be more than 30%. Neuropathy occurs in NIDDM and IDDM, but may develop sooner after diagnosis in NIDDM. Medication selection should be individualized, considering side effects, potent beneficial or deleterious effects on comorbidities, and whether prompt onset of pain relief is necessary.

Key words: Diabetes Mellitus, Neuropathic Pain.

Introduction

Neuropathic pain develops as a result of lesions or disease affecting the somatosensory nervous system either in the periphery or centrally. Examples of neuropathic pain include painful polyneuropathy, postherpetic neuralgia, trigeminal neuralgia, and post-stroke pain. Clinically, neuropathic pain is characterized by spontaneous ongoing or shooting pain and evoked amplified pain responses after noxious or non-noxious stimuli. Methods such as questionnaires for screening and assessment focus on the presence and quality of neuropathic pain. Management of neuropathic pain requires an interdisciplinary approach, centred around pharmacological treatment. A better understanding of neuropathic pain and, in particular, of the translations of pathophysiological mechanisms into sensory signs will lead to a more effective and specific mechanism-based treatment approach. Others may have symptoms such as pain, tingling, or numbness—loss of feeling—in the hands, arms, feet, and legs. Nerve problems can occur in every organ system, including the digestive tract, heart, and sex organs.[1-3]

Classification of Diabetic Neuropathy

Diabetic neuropathy is heterogeneous (Thomas and Tomlinson 1993). [Table 2] shows one classification. Importantly many patients present with >1 form of neuropathy, e.g. polyneuropathy and carpal tunnel syndrome (CTS).[1]

Diagnosis

~20% of neuropathy patients remain without a etiologic diagnosis after routine lab studies including B12, folate, ANA, rheumatoid factor, ESR, immunofixation electrophoresis, RPR, TSH,CBC, and comprehensive metabolic panel. Recent reports suggest that some of these have impaired glucose tolerance (IGT) with glucose of 144-199 mg/dl in a 2 hr glucose tolerance test (Novella et al 2001, Russell and Feldman 2001, Singleton et al 2001). The more convenient test of HbA1c is insensitive. 0% of diabetics have other reasons for neuropathy; these causes must be sought.[1]

Pathogenesis

The causes are probably different for different types of diabetic neuropathy. Researchers are studying how prolonged exposure to high blood glucose causes nerve damage. Nerve damage is likely due to a combination of factors: metabolic factors, such as high blood glucose, long duration of diabetes, abnormal blood fat levels, and possibly low levels of insulin; neurovascular factors, leading to damage to the blood vessels that carry oxygen and nutrients to nerves; autoimmune factors that cause inflammation in nerves; mechanical injury to nerves, such as carpal tunnel syndrome; inherited traits that increase susceptibility to nerve disease; lifestyle factors, such as smoking or alcohol use.[3]

Treatment and primary and secondary Prevention

Control of hyperglycemia delays the appearance of neuropathy and slows progression. The Diabetes Control and Complications Trial found that intensive IDDM therapy reduced the frequency of neuropathy by 60% over 5 years (DCCT Research Group 1993). Pancreatic transplantation appears to halt the progression of diabetic neuropathy, but does not clearly reverse existing neuropathy (Kennedy et al 1990, Navarro et al 1997).[1]

Pain Management

Small Fiber Polyneuropathy
Pain is the main complaint, most commonly distally, described in similar terms as discussed above. Autonomic dysfunction is frequently present. On exam there is distal sensory loss affecting pain and temperature, with relative preservation of the large fiber functions vibration, proprioception, reflexes and strength. NCS are normal or minimally abnormal, since such tests assess primarily large, fast-conducting fibers. Quantitative sensory testing (QST) is abnormal in 60%-100%. Autonomic neuropathy affects the nerves that control the heart, regulate blood pressure, and control blood glucose levels. Autonomic neuropathy also affects other internal organs, causing problems with digestion, respiratory function, urination, sexual response, and vision. In addition, the system that restores blood glucose levels to normal after a hypoglycemic episode may be affected, resulting in loss of the warning symptoms of hypoglycemia. Autonomic neuropathy affects the nerves in the heart, stomach, intestines, bladder, sex organs, sweat glands, eyes, and lungs.

**Neuropathy and Pain**

In some diabetic patients, onset of pain is attributable to acute normalization of blood sugar at the onset of insulin therapy (insulin neuritis). While in others it coincides with dramatic weight loss. Aside from these particular conditions, it is frequently estimated that 10-20% of patients with diabetic neuropathy exhibit pain as one of the symptoms. This number may well be an underestimation.

**Peripheral neuropathy**

Peripheral neuropathy, also called distal symmetric neuropathy or sensorimotor neuropathy, is nerve damage in the arms and legs. Feet and legs are likely to be affected before hands and arms. Many people with diabetes have signs of neuropathy that a doctor could note but feel no symptoms themselves. Symptoms of peripheral neuropathy may include numbness or insensitivity to pain or temperature, a tingling, burning, or prickling sensation sharp pains or cramps, extreme sensitivity to touch, even light touch, loss of balance and coordination.

**Pain Relief**

Treatment of painful diabetic neuropathy are oral medications. People with severe nerve pain may benefit from a combination of medications or treatments and should consider talking with a health care provider about treatment options. Medications used to help relieve diabetic nerve pain include tricyclic antidepressants, such as amitriptyline, imipramine, and desipramine (Nortryptalin, Pertofoam; other types of antidepressants, such as duloxetine (Cymbalta), venlafaxine, bupropion (Wellbutrin), paroxetine (Paxil), and citalopram (Celexa); anticonvulsants, such as pregabalin (Lyrica), gabapentin (Gabaron, Neurontin), carbamazepine, and lamotrigine (Lamictal); opioids and opioid-like drugs, such as controlled-release oxycodeone, an opioid; and tramadol (Ultran), an opioid that also acts as an antidepressant. Duloxetine and pregabalin are approved by the U.S.

Antiepileptics

Gabapentin and pregabalin are effective in diabetic PPN, with dose-dependent effects for pregabalin (several negative studies for 150 mg/day, mainly positivestudies for 300–600 mg/day) and similar efficacy between gabapentin and the TCA nortriptyline in a recent class I study. Side effects include dizziness, somnolence, peripheral oedema,
weight gain, asthenia, headache and dry mouth. In a recent comparative trial, only two side effects differentiated gabapentin and nortriptyline: dry mouth (more frequent with nortriptyline) and concentration disorders (more frequent with gabapentin).  

Opioids agonist

Oxycodone, tramadol and tramadol/acetaminophen combination reduce pain in diabetic PPN. Side effects include mainly nausea and constipation, but long-term use of opioids may be associated with misuse (2.6% in a recent 3-year registry study of oxycodone in mainly diabetic NP, although higher rates were also reported).  

Tramadol should be used with caution in elderly patients because of risk of confusion and is not recommended with drugs acting on serotonin reuptake such as SSRIs. The tramadol/acetaminophen combination appears better tolerated.

Antidepressants

The Opioids analgesics have unequivocally shown effectiveness in the treatment of PDPN. While these agents, specifically tramadol, oxycodone, and morphine, are recommended as second-line therapy in recent practice guidelines, their long-term utility is yet to be elucidated. Tramadol, a unique mu-opioid agonist with serotonergic reuptake inhibition, is supported by a large clinical database in PDPN studies.

**Methadone**

A potent mu-opioid agonist, additionally possesses numerous other pharmacologic properties such as serotonin and norepinephrine reuptake inhibition, and n-methyl-D-aspartate inhibition, proposed mechanisms of central sensitization, allodynia, and neural plasticity associated with long-standing diabetes.

**Current Therapies**

In the absence of an established pathogenic mechanism for either neuropathy or pain, there is no prophylactic therapy against painful diabetic neuropathy. Only duloxetine (Cymbalta) and pregabalin (Lyrica) currently have FDA-approved labeling for treating painful diabetic neuropathy.

**Antidepressants**

While antidepressants maybe classified in a variety of ways, we will use the classifications of selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and atypical antidepressants (those which do not conveniently fall within one of these groups).

**Anticonvulsants**

The anticonvulsants have more recently become considered first-line for the treatment of PDPN, largely due to a reduced side effect profile compared to antidepressants and the generic availability of gabapentin. Anticonvulsants, as a class, typically possess more drug interactions, with the exception of the gabapentinoids (pregabalin and gabapentin), compared to their antidepressant counterparts.

Zonisamide

Should not be used in patients with adocumented sulfa medication allergy while toproimate is not prone to this sensitivity. Oxcarbazepine, a derivative of carbamazepine, exhibits similar sodium channel blockade with reduced incidence of severe hepatotoxicity and blood dyscrasias. The risk of a Steven Johnson Syndrome rash still exists, as well as hyponatremia. No serum drug monitoring is required and the medication is usually well-tolerated when titrated quickly.

**Antipsychotics**

The introduction of the “atypical” antipsychotics, so-called because of their diverse pharmacology separate from that of pure dopaminergic blockade, resulted in the investigation of these agents for the treatment of pain of a neurogenic origin. Numerous atypical antipsychotics have been studied for chronic noncancer pain syndromes, although few have focused on PDPN.

**Anesthetics/ anti-arrhythmic**

The anesthetic anti-arrhythmics are perhaps the most under-utilized of the potential strategies for alleviation of neuropathic pain associated with diabetes. Although careful monitoring by experienced practitioners is paramount, Lidocaine, mexilitine, and tocainide have all shown benefit for PDPN in smaller, RCTs. Some pain clinicians recommend the administration of a lidocaine infusion to assess the potential response to oral mexilitine, a lidocaine congener. Others report success with periodic lidocaine infusions without transition to an oral alternative.

**Vasodilators**

As the numerous pathophysiologic theories for PDPN, emerged over the past two decades, several treatments, such as direct vasodilators, were investigated for analgesia in this pain syndrome. Isosorbide dinitrate spray is recommended as a second-line therapy option for PDPN based on the AAN evidenced based guidelines.

**Conclusion**

Diabetic neuropathies are nerve disorders caused by many of the abnormalities common to diabetes, such as high blood glucose. Treatment first involves bringing blood glucose levels within the normal range. Good blood glucose control may help prevent or delay the onset of further problems. Foot care is an important part of treatment. Treatment also includes pain relief and other medications as needed, depending on the type of nerve damage.

**References**
1. Thomas FP. The Spectrum of Diabetic Neuropathy.